The word “undruggable” has hampered pursuit of the most compelling biological targets, drawing from established opinion that pharmacological modulation was not possible. Scientists at Dogma Therapeutics (“Dogma”) were determined to challenge this assumption. Dogma has discovered an orally-bioavailable small molecule PCSK9 inhibitor. By strategically focusing on small molecule inhibitors, Dogma can readily combine their compounds with current standard of care and dramatically disrupt the health economics of PCSK9-based therapies.
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment. The additional funding from Mercia Technologies PLC, the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential, is part of a circa £2.4 million syndicated investment round.
London, UK, 21st May 2019 / The £27m UK Innovation & Science Seed Fund (UKI2S) and Innovate UK (IUK) have launched a joint initiative, the UKI2S Innovate Accelerator. With £10m of IUK funding to be used alongside direct equity investment by UKI2S, the new scheme is designed to boost some of the UK’s most exciting young companies.
Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and an extended programme of mentoring and support
TTP enables development of MosaiQ™ diagnostic platform for transfusion typing and disease screening
Cambridge, UK, 20 May 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd (NASDAQ:QTNT), a commercial-stage diagnostics company committed to transforming transfusion diagnostics and beyond – to develop and implement a state-of-the-art manufacturing facility for Quotient’s proprietary MosaiQ™ system.
Cambridge, UK, 20 May 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension (PAH), to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes. This development program will be solely funded by Actelion.
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional
£14 million bringing the total Series A financing to £30 million.
The financing includes funding from new investor, Seroba Life Sciences (“Seroba”). STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise.
Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has reported record-breaking growth in its overseas turnover in the 12-months since it was recognised with one of the UK’s most prestigious awards, The Queen’s Awards for Enterprise.
Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.